Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Aprocitentan on Rosuvastatin PK in Healthy Males
NCT03245229Phase 1Completed
- Sponsor
- Idorsia
- Start
- Aug 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aprocitentan in hypertension (HTN), sponsored by Idorsia. Primary endpoints: Maximum plasma concentration of rosuvastatin, Time to reach Cmax of rosuvastatin and 4 more. Started Aug 2017; status: completed.
02
Drugs
aprocitentan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03245229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245229.